You can buy or sell ITCI and other stocks, options, ETFs, and crypto commission-free!
Intra-Cellular Therapies Inc. Common Stock, also called Intra-Cellular Therapies, is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Read More Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.
New York, New York
52 Week High
52 Week Low
Stock Price, News, & Analysis for Intra-Cellular Therapies
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. The company is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, and other neuropsychiatric and neurological disorders. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipol...
Simply Wall StFeb 27
Does Intra-Cellular Therapies, Inc.’s (NASDAQ:ITCI) CEO Salary Reflect Performance?
Sharon Mates has been the CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) since 2013. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that the business demonstrates. Third, we’ll reflect on the total return to shareholders over three years, as a second measure of business performance. The aim of all this is to consider the appropriateness of CEO pay levels. See our latest analysis for Intra-Cellular Therapies How Does Sharon M...
The Motley FoolFeb 27
Intra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript
Intra-Cellular Therapies Inc (NASDAQ:ITCI) Q4 2018 Earnings Conference Call , 8:30 a.m. ET Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Operator Good morning, ladies and gentlemen, and welcome to the Intra-Cellular Therapies Fourth Quarter and Full Year Ended December 31st 2018 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later there will be a question-and-answer session and instructions will follow at that time. ...
Expected May 2, Pre-Market